BioAge Announces First Cohort Dosed in Phase Ib Clinical Trial of the Apelin Receptor Agonist BGE-105, Under Development for Muscle Aging Indications

BioAge Labs, Inc. announced that the first cohort has been dosed in a Phase Ib trial of BGE-105, a highly selective and potent small-molecule agonist of the apelin receptor APJ, which regulates multiple aspects of muscle metabolism, growth, and repair.